Statistical Science Lead, Solid Tumor

About Astellas

Astellas is a global life sciences company committed to turning innovative science into value for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Learn more at

The Global Statistical Lead (GSTATL) for Solid Tumor Oncology is a compound level leader within the Quantitative Science & Evidence Generation (QSEG) organization, accountable for driving the statistical and analytical strategy for a compound or indication across its full development lifecycle.

This position leads a cross-functional, integrated quantitative team supporting evidence generation and decision-making, with responsibility spanning clinical trial statistics, exploratory statistics, medical affairs statistics, real-world evidence (RWE), safety/pharmacovigilance (PV) statistics, statistical programming, biomarker statistics, and advanced analytics.

The role ensures consistency and scientific excellence across studies, indications, and evidence types—while enabling innovation in statistical methodology, clinical development optimization, and external engagement. The GSTATL plays a key role in regulatory and payer strategy, as well as internal governance and portfolio planning for solid tumor assets.

• Serve as the compound-level statistical lead for solid tumor oncology, responsible for end-to-end quantitative strategy supporting clinical development, evidence generation, and regulatory/payer interactions.
• Lead development of integrated statistical strategies across all relevant study types and functions (e.g., phase 1b/2 signal-seeking, pivotal, exploratory, RWE, post-marketing).
• Align statistical and analytical approaches with the target product profile (TPP), development strategy, and external evidence needs.
• Lead and coordinate statistical and analytics contributions from a broad QSEG team, including clinical trial biostatisticians, exploratory oncology statisticians, medical affairs statisticians, statistical programmers, biomarker/statistical genetics experts, RWE analysts, safety/PV statisticians, and advanced analytics specialists.
• Ensure scientific alignment, quality, and integration across all statistical contributions at the compound level.
• Represent Astellas on all statistical matters in global regulatory interactions (e.g., FDA, EMA, PMDA) and guide the preparation of statistical content for regulatory submissions, briefing packages, and health technology assessment dossiers.
• Lead the development of statistical components of payer evidence strategies, including indirect comparisons and external control methodologies.
• Champion oncology-appropriate innovations such as Bayesian designs, adaptive trial designs, external controls, tumor-agnostic approaches, and AI/ML tools.
• Promote exploratory data analysis, modeling, and simulation to support rapid development decisions in Solid Tumor trials.
• Integrate clinical, biomarker, safety, and real-world evidence to drive cohesive, data-driven development and access strategies.
• Mentor statisticians and analytics professionals across QSEG, supporting scientific development and career growth, sharing knowledge and best practices, and contributing to internal training and talent pipeline initiatives.
• Participate in global asset governance and development team meetings, influencing decisions with rigorous statistical insight, collaborating with Clinical Development, Medical Affairs, Regulatory, Market Access and Commercial teams, and leading or contributing to internal initiatives such as standardization efforts, methodology forums, and innovation networks.

• Advanced degree (PhD, MD, MBA or equivalent) in Oncology, Life Sciences or a related field.
• Minimum 8 years of experience in pharmaceutical R&D, external innovation, academic collaboration or scientific partnering.
• Strong understanding of oncology drug discovery, translational science and modality platforms (e.g., next‑gen ADCs,…